



Mr Shri Jagat Prakash Nadda  
Union Minister  
Ministry of Health & Family Welfare  
155 - A, Nirman Bhavan  
New Delhi - 110108  
India

28 November 2016

Dear Minister,

**Re: Approval of Measles Rubella Vaccine Support for India**

We are writing in relation to India's application to Gavi, the Vaccine Alliance, for Measles Rubella Vaccine (MR) campaign support, which was submitted to the Gavi Secretariat in May 2016. We attach an amended version of the Decision Letter dated 17 October 2016, which contains a revised number of vaccine doses following the finalisation of a vaccine donation agreement between Serum Institute of India and Gavi.

In addition to the Gavi commitment of US\$115m for MR support, Serum Institute of India has donated 20m MR vaccine doses for the Government of India. This is reflected in the amended Decision Letter, which now shows an increased commitment of US\$127,341,015.

In calculating the doses available to India, we have used the current price for the MR vaccine, which includes taxes levied on the vaccine (6% excise duty and 5% tax for doses specific to Maharashtra state, one of the states involved in the campaign). We are looking into this further to understand whether there are tax exemptions available for vaccines purchased by UNICEF.

Finally, we note that the Gavi Board's decision to provide catalytic support for India's MR programme is subject to the provisions of Annex 6 of the PFA, in particular the commitments of the Government of India to fund additional costs required as well as scale-up of the programme, and to implement the programme as set out in the approved Performance Framework.

Please do not hesitate to contact the Senior Country Manager for India, Carol Szeto ([cszeto@gavi.org](mailto:cszeto@gavi.org)), if you have any questions or concerns.

We remain at your disposal for any further enquiry.

Yours sincerely,



Hind Khatib-Othman  
Managing Director, Country Programmes

Cc:

PS, The Minister of Health and Family Welfare  
PS, The Minister of Finance  
Secretary, Ministry of Health and Family Welfare  
Additional Secretary, MD NHM, Ministry of Health and Family Welfare  
Joint Secretary, Ministry of Health and Family Welfare  
Deputy Commissioner (Immunization); MoHFW  
Deputy Commissioner (UIP), MoHFW  
WHO Country Representative  
UNICEF Country Representative  
WHO HQ  
UNICEF Programme Division  
UNICEF Supply Division

## India Support for Measles Rubella Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> India			
<b>2.</b> Grant number: 17-IND-18a-X			
<b>3.</b> Date of Decision Letter: 28 November 2016 (this letter replaces the Decision Letter dated 17 October 2016)			
<b>4.</b> Date of the Partnership Framework Agreement: 12 June 2015			
<b>5.</b> Programme title: NVS, Measles Rubella Campaign			
<b>6. Vaccine type:</b> Measles Rubella			
<b>7.</b> Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
<b>8.</b> Programme duration <sup>1</sup> : 2017			
<b>9.</b> Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2017	Total <sup>2</sup>	
Programme Budget Gavi (US\$)	US\$115,000,000	US\$115,000,000	
Programme Budget Gavi - "Donated Doses" (US\$)	US\$12,341,015	US\$12,341,015	
Programme Budget Gavi - TOTAL	US\$127,341,015	US\$127,341,015	
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable			
<b>11.</b> Indicative annual amounts: (subject to the terms of the Partnership Framework Agreement) <sup>3</sup>			
Type of supplies to be purchased with Gavi funds in each year	2017 - Gavi	2017- Gavi "Donated Doses"	2017- Gavi TOTAL
Number of Measles Rubella vaccines doses	176,923,100	20,000,000	196,923,100
Annual Amounts (US\$)	US\$115,000,000	US\$12,341,015	US\$127,341,015
<b>12.</b> Procurement agency <sup>4</sup> : UNICEF			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme. The Programme budget comprises \$115 million as committed to India as part of the India Partnership Strategy (adjusted for budget variance) and \$12 million under the donation agreement with the manufacturer. This is based on the current price of the vaccine, as well as taxes and freight costs.

<sup>3</sup> This is the amount that Gavi has approved.

<sup>4</sup> UNICEF will not be requested to facilitate the delivery of any "Donated doses".

<b>13. Self-procurement:</b> Not applicable	
<b>14.</b> Co-financing obligations: Not applicable	
<b>15.</b> Operational support for campaigns: Not applicable	
<b>16. Additional reporting requirements:</b> The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:	
Reports and other information	Due dates
SIA technical report	Within three months of the finalisation of the campaign
Post campaign coverage survey report and actual expenditures report	As soon as available
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance	To be agreed with Secretariat
<b>17.</b> Financial clarifications: Not applicable	
<b>18. Other conditions:</b> Gavi's catalytic support for India is subject to the provisions in Annex 6 of the Partnership Framework Agreement, and in particular:	
<ul style="list-style-type: none"> <li>• The commitments of the Government of India to provide financing to fund the additional costs required for each programme that is funded with the Partnership Support and to scale up the programmes; and</li> <li>• Implementation of the programmes in line with the timelines, milestones and indicators set out in the performance framework.</li> </ul>	

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
28 November 2016